Evaluation of (68)Gallium- DOTATATE PET/CT for Detecting Primary and Metastatic Neuroendocrine Tumors

Trial Profile

Evaluation of (68)Gallium- DOTATATE PET/CT for Detecting Primary and Metastatic Neuroendocrine Tumors

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs Gallium 68-DOTATATE (Primary)
  • Indications Neuroendocrine tumours
  • Focus Diagnostic use
  • Most Recent Events

    • 13 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 13 Jan 2017 Planned End Date changed from 1 Sep 2021 to 1 Dec 2022.
    • 22 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top